20260819_PRDA_Laporan Informasi dan Fakta Material_32121388_lamp2.pdf

The buyback will be fully funded by Prodia’s internal cash and therefore is not expected to disrupt the
Company’s operational activities, expansion plans, or ability to meet its financial obligations. The
Company remains committed to maintaining financial discipline while supporting sustainable business
growth.

As stated in the Company’s Information Disclosure, the buyback is a strategic measure aimed at
supporting long-term growth, maintaining share price stability, strengthening market confidence, and
optimizing the Company’s capital structure to deliver sustainable value to shareholders. The Company
also believes that the buyback will not have a material impact on its operational activities or financial
performance, as it is supported by adequate working capital and cash flow.

The Company extends its appreciation for the continued trust of all shareholders and will remain focused
on strengthening its business fundamentals, implementing good corporate governance, and creating
long-term value for all stakeholders.

#Prodia #PRDA #Buyback #CapitalMarket #SustainableGrowth

                                                                             ******
About PT Prodia Widyahusada Tbk.

Prodia Clinical Laboratory was first established in Solo on May 7, 1973, by a group of idealistic individuals with backgrounds in pharmacy. Since its inception, Dr. Andi
Widjaja, MBA, together with the other founders, has remained committed to delivering high-quality laboratory test results with wholehearted service.


All Prodia branches have obtained accreditation at both national and international levels. One of these is accreditation from the College of American Pathologists
(CAP), a U.S.-based professional organization in the field of laboratory medicine with international recognition, which Prodia has maintained for 10 consecutive
years. Through CAP accreditation, the quality standards of clinical laboratories are assessed against international benchmarks, enabling Prodia’s test results to be
recognized not only in Indonesia but also internationally. This demonstrates that the quality of Prodia’s laboratory test results is on par with international laboratory
standards.


On December 7, 2016, the Indonesia Stock Exchange (IDX) officially listed Prodia’s shares, making the Company the 15th issuer to be listed on the IDX in 2016 under
the ticker code “PRDA.” Through its Initial Public Offering (IPO), Prodia offered 187.5 million shares and raised IDR1.22 trillion in proceeds.


As of June 30, 2026, Prodia operated a network of 392 service outlets across 82 cities, 111 regencies, and 34 provinces throughout Indonesia. These include Prodia
Health Care (PHC), a wellness clinic based on personalized medicine, as well as specialty clinics comprising Prodia Children’s Health Centre (PCHC), Prodia Women’s
Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).


Prodia has also introduced various customer contact channels under Kontak Prodia, including the 1500-830 call center and Tanya Prodia (TANIA), an online virtual
personal assistant accessible via WhatsApp at 08551500830, Telegram at @prodia.id, Facebook Messenger at @prodia.id, and the Prodia Web Widget available on
the Prodia website. Prodia’s services can also be accessed through the U by Prodia application, available for download on the App Store and Google Play Store.


For further information, please visit the Prodia website or contact:

Fenty Diah P                                                              Mella Melia
Corporate Secretary Manager                                               Investor Relation Manager
PT Prodia Widyahusada Tbk.​                                               PT Prodia Widyahusada Tbk
Ph.    +62-21-3144182                                                     Ph: +62-21-3144182
Email corporate.secretary@prodia.co.id                                    Email : investor.relation@prodia.co.id